Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant polycystic kidney disease (ADPKD) is the autosomal dominant form of polycystic kidney disease. The packet lists the abbreviation ADPKD and the alternative name congenital biliary ectasias as synonyms. According to expert review (GeneReviews), all individuals with ADPKD develop cysts within the kidneys, and severity varies substantially between affected people, with significant variability even within the same family.
The packet gives a prevalence category of common, at 1 to 5 per 10,000 people. Expert review separately describes a prevalence at birth of approximately 1 in 1,000 and states that the condition affects approximately 300,000 persons in the United States. The two figures come from different sources and are reported as stated by each. The packet also lists several related subtypes, including polycystic kidney disease 1, 2, 3, 6, 7, and 8.
Data assembled from 6 of 12 sources · Last updated Nov 18, 2026, 8:43 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
The packet contains no structured phenotype list, so this description rests on the clinical description in expert review. Kidney involvement is central: kidney cysts develop and enlarge over time, and the kidney manifestations include abnormal kidney function, hypertension, kidney pain, and kidney insufficiency, all described as directly related to cyst development and enlargement. In a prospective imaging study summarized there, total kidney volume and cyst volume increased exponentially, and larger kidneys at baseline were associated with faster later enlargement.
Expert review also describes cysts outside the kidney, particularly in the liver, and notes cysts can occur in the seminal vesicles, pancreas, and arachnoid membrane. Hypertension before age 35 years and an intracranial aneurysm are listed among findings that raise suspicion of the condition. Because the disease is progressive, few cysts may be evident in childhood or young adulthood.
Occasionally, enlarged and echogenic kidneys are detected prenatally in a fetus at risk; expert review states that the course in these cases is often more favorable than the kidney size suggests during childhood, although end-stage kidney disease develops earlier than is typical for adult-onset disease. It reports earlier end-stage kidney disease in males than in females in the cited analyses.
The packet's gene field is empty, so no specific genes are named in this report. According to expert review, in most affected families ADPKD is caused by a heterozygous pathogenic variant in one of two principal genes and is inherited in an autosomal dominant manner; more rarely it is attributed to heterozygous pathogenic variants in other genes. The packet's subtype list reflects this genetic heterogeneity.
Expert review states that most individuals diagnosed with ADPKD have an affected parent and that 10 to 20 percent of diagnosed individuals have the disorder as the result of a de novo pathogenic variant. It describes genotype-phenotype relationships in which about half of in-frame variants in the principal gene are hypomorphic and associated with milder disease, and truncating variants are associated with more severe disease than nontruncating variants. Penetrance is described as age and genotype dependent, with multiple bilateral kidney cysts in older adults close to 100 percent penetrant. Rarely, biallelic disease involving at least one hypomorphic variant has been reported, including early-onset disease that may be mistaken for autosomal recessive polycystic kidney disease.
Expert review states that diagnostic criteria are discussed in an executive summary of the KDIGO Controversies Conference. Findings that raise suspicion include multiple bilateral kidney cysts without features of a different cystic kidney disease, cysts in other organs, enlarged kidneys or liver on examination, hypertension before age 35 years, an intracranial aneurysm, and a family history consistent with autosomal dominant inheritance; the absence of a known family history does not rule out the diagnosis.
According to expert review, the diagnosis is established by qualifying imaging findings together with an affected first-degree relative, or by a pathogenic variant in an associated gene. Age-specific ultrasound criteria for people with an affected first-degree relative are three or more kidney cysts at age 15 to 39 years and two or more cysts in each kidney at age 40 to 59 years. Sensitivity of ultrasound is described as lower in some genetic forms. Magnetic resonance imaging criteria are described as useful when ultrasound is equivocal, with more than ten cysts sufficient at ages 16 to 40 years in people at 50 percent risk.
The differential diagnosis in expert review includes benign simple kidney cysts, polycystic liver disease, Alport syndrome, Birt-Hogg-Dube syndrome, Hajdu-Cheney syndrome, oral-facial-digital syndrome type 1, and autosomal recessive polycystic kidney disease.
According to expert review, current therapy for ADPKD is aimed at slowing the progression of declining kidney function and reducing illness and death from kidney and extra-kidney complications.
The packet lists two FDA-approved products with tolvaptan, a vasopressin V2 receptor antagonist, as the generic name: JYNARQUE (approved in 2018) and SAMSCA (approved in 2009), both with active market status. Expert review states that studies have shown tolvaptan can slow the increase in kidney volume and delay decline in kidney function, reports liver enzyme elevations in approximately 5 percent of individuals that reversed on withdrawal, and describes guidelines that focus on people with rapidly progressive disease.
For hypertension, expert review states that the agents of choice have not been clearly established and that ACE inhibitors and angiotensin II receptor blockers may be superior in people with preserved kidney function. Additional measures it lists for delaying end-stage kidney disease include lipid control, moderate sodium intake, and dietary protein restriction. It also lists circumstances associated with concern, including long-term exposure to nephrotoxic agents such as NSAIDs, a high-salt diet, smoking, and obesity.
The packet also lists many investigational compounds with FDA orphan drug designation for ADPKD, including lixivaptan, venglustat, tesevatinib, and bardoxolone methyl. Orphan designation is not approval; these are described only as under development.
57 trials found
Expert review describes ADPKD as a progressive condition with substantial variability in severity between individuals. The packet includes no natural history field and no certified life expectancy. Expert review reports group-level study observations, such as a mean age at end-stage kidney disease of about 55.6 years with truncating variants versus 67.9 years with nontruncating variants in the more commonly involved gene, and differences by sex. These figures describe study populations, not any single person. Kidney volume is described as a strong predictor of later decline in kidney function, and expert review lists earlier diagnosis, early hypertension, and large total kidney volume among poor prognostic factors.
The packet certifies active clinical research on ADPKD, with sponsors that include academic centers and pharmaceutical companies. Listed studies include NCT06902558, a phase 2 study of ABBV-CLS-628 sponsored by Calico Life Sciences, and NCT07228364, a phase 1 study of AZD1613 sponsored by AstraZeneca, both recruiting. Other listed studies are biomarker-focused or observational, such as NCT07217158 from Mayo Clinic. The packet's publication digest indicates that the literature is dominated by basic science and preclinical work. Active clinical trials for this condition are listed on ClinicalTrials.gov.
AI-curated news mentioning autosomal dominant polycystic kidney disease
Updated Oct 20, 2026
A new analytics platform, MEDA-PKD, has been developed for precision care in autosomal dominant polycystic kidney disease. This dynamic, real-time tool aims to enhance patient management and treatment outcomes.
A case study highlights extensive parenchymal brain calcification in a patient with autosomal dominant polycystic kidney disease and stage 5 chronic kidney disease. This research contributes to understanding the neurological implications of these conditions.
A case report highlights biallelic PKD1 mutations leading to neonatal death in a preterm infant, emphasizing the severe implications of very early-onset autosomal dominant polycystic kidney disease (ADPKD). This study contributes to the understanding of genetic factors in neonatal outcomes.